Dr. Adrian Kinkaid, CEO
Adrian has extensive experience in the life sciences sector, with particular expertise in affinity reagents, including antibodies, affimers and aptamers. He has developed a thorough understanding of the field and considers MIPs as a cost effective and high quality alternative to existing reagents due especially to their robustness and speed of development.
Prior to joining MIP Diagnostics, Adrian worked as Chief Commercial Officer for Promexus, a protein biotherapeutics company based on affimer technology from Avacta Life Sciences. Before this he was Head of Technology Access and then Strategic Market Development Leader for Abcam, the leading provider of research antibodies.
Adrian’s industrial experience started with agrochemical and pharmaceutical discovery where he developed a range of different biochemical and cell based assays mainly for high throughput screening applications. Adrian is also a Founding Member of ELRIG (European Laboratory Research and Innovation Group) a not-for-profit organisation that holds conferences and events for thought leadership in the life science and drug discovery communities. Adrian served two terms as Chairman, during which time he established the flagship Drug Discovery event, which is now the leading conference of its kind in Europe.